Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Modern Rheumatology|July 15, 2016
Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritisKeiko Funahashi, Satoru Koyano, Hirotoshi Echizen, et al.Biological & Pharmaceutical Bulletin|December 4, 2003
Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203X and Y27632 on cultured basilar artery smooth muscle cellsTomoaki Yamaguchi, Kazuhiko Oishi, Masaatsu Uchida, et al.Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 4, 2022
[Analysis of Information on Drug Adverse Reactions Using U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)]Daisuke Nango, Tuyoshi Sekizuka, Makoto Goto, et al.Journal of Pharmaceutical Health Care and Sciences|March 13, 2019
Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS)Daisuke Nango, Yukifumi Hirose, Makoto Goto, et al.Clinical Pharmacology and Therapeutics|August 2, 2002
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisolHideki Ushiama, Hirotoshi Echizen, Shinobu Nachi, et al.British Journal of Clinical Pharmacology|June 8, 2018
Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patientsToshinori Hirai, Toshimasa Itoh, Toshimi Kimura, et al.European Journal of Drug Metabolism and Pharmacokinetics|June 3, 2019
Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of LifeHirokazu Nakayama, Masahiro Suzuki, Toshiaki Kato, et al.Plos One|July 25, 2020
Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysisMasahiro Takahashi, Misa Shibasaki, Hirotoshi Echizen, et al.Therapeutic Drug Monitoring|January 29, 2008
Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeksHirokazu Nakayama, Hirotoshi Echizen, Masayo Tanaka, et al.European Journal of Drug Metabolism and Pharmacokinetics|July 21, 2018
Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of LifeHirokazu Nakayama, Hirotoshi Echizen, Ryuichi Ogawa, et al.Pageof 6